

In the Specification:

Please amend the specification as shown:

Please insert the following on page 1, line 9:

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on February 24, 2011, is named 34395813.txt and is 2,047 bytes in size.

Please delete the paragraph on page 26, line 25 to page 27, line 4 and replace it with the following paragraph:

Moller, et al., Eur. J. Biochem. 269:1444-55 (Mar. 2002) has used NMR spectroscopy to study the binding of the SM3 antibody to the pentapeptide MUC1 epitope PDTRP (**AAs 6-10 of SEQ ID NO: 1**) and to the related glycopentapeptide in which the threonine is O-lined to alpha-d-GalNAc. Moller found that the PDT interacted with the SM3 antibody more strongly than did the RP, suggesting that the RP would be more tolerant of mutation. In contrast, the glycopeptide interacted with SM3 using all of its amino acids, although the strongest effect was with the Pro1. Docking studies were conducted; these could be performed with mutant peptides for which 3D structures are deducible or determined.

Please delete the paragraph on page 31, lines 8-16 and replace it with the following paragraph:

Each MUC1 epitope in question may correspond to an epitope of the variable tandem repeat region, or to an epitope outside that region. The former include RPAPGS (AAs 9-14 of SEQ ID NO:1), PPAHGVT (AAs [[4-10]]**17-20 followed by AAs 1-3** of SEQ ID NO:[7]**1**) and PDTRP (AAs 6-10 of SEQ ID NO:1). The sequence PDTRPAPGS (AAs 6-14 of SEQ ID NO:1) is of particular interest, as it includes two overlapping epitopes. The PDTRP (**AAs 6-10 of SEQ ID NO: 1**) sequence forms the tip of a protruding knob exposed to solvents and forming a stable type II beta-turn.

Please delete the paragraph on page 31, lines 20-25 and replace it with the following paragraph:

Preferably, the immunogen comprises the polymorphic epitope P[D/E] [T/S]RP or a substantially identical mutant thereof. ("Substantially identical" is defined in Koganty4A-PCT, PCT/US03/10750, filed April 9, 2003.) More preferably it comprises PDTRP (**AAs 6-10 of SEQ ID NO: 1**) or a substantially identical mutant thereof.